Fig. 4
From: Investigating PPT2’s role in ovarian cancer prognosis and immunotherapy outcomes
The prognosis value of PPT2 in OC. (A-B) Kaplan-Meier survival curve for comparing the high and low expression of PPT2 in an in-house OC cohort associated with OS, and PFS respectively. (C) Kaplan-Meier survival curves for comparing the high and low expression of PPT2 associated with OS in datasets GSE23554, GSE26712, GSE32063, GSE51088, GSE63885, GSE140082, and TCGA respectively. (D) Kaplan-Meier survival curves for comparing the high and low expression of PPT2 associated with PFS in datasets GSE32063, and GSE140082 respectively. (E) Kaplan-Meier survival curves for comparing the high and low expression of PPT2 in the TCGA dataset associated with DSS. (F) Cox regression survival analysis in pan-cancer